ArticleTherapeutics and clinical risk management2008
Treatment strategies in mucous membrane pemphigoid.
Article in Therapeutics and clinical risk management, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 69 citations in OpenAlex.
- Challenges and advances in ocular mucous membrane pemphigoid (OMMP); from pathogenesis to treatment strategies.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Review
- Analysis of a Combination Therapy Protocol for the Treatment of Oral Mucous Membrane Pemphigoid: A Retrospective Case Series Study.International journal of dentistry · 2024Article
- [Ocular mucous membrane pemphigoid].Die Ophthalmologie · 2023Article
- Simplifying differential diagnoses of orofacial conditions - a guide to surgical sieves and red flags.British dental journal · 2021Article
- Ocular cicatricial pemphigoid (Review).Experimental and therapeutic medicine · 2020Review
- Systemic disease or periodontal disease? Distinguishing causes of gingival inflammation: a guide for dental practitioners. Part 1: immune-mediated, autoinflammatory, and hereditary lesions.British dental journal · 2019Article
- Dry Eye Disease: A Review of Epidemiology in Taiwan, and its Clinical Treatment and Merits.Journal of clinical medicine · 2019Review
- Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology.Anais brasileiros de dermatologia · 2019Article
- Inflammatory Stress Causes N-Glycan Processing Deficiency in Ocular Autoimmune Disease.The American journal of pathology · 2019Article
- Atypical case of mucous membrane pemphigoid in a 26-year-old man.BMJ case reports · 2018Article
- Adrenocorticotropic hormone analogue as novel treatment regimen in ocular cicatricial pemphigoid.American journal of ophthalmology case reports · 2018Article
- Successful treatment of mucous membrane pemphigoid with bortezomib.JAAD case reports · 2018Article
- Recurrent Aphthous Stomatitis: A Review.The Journal of clinical and aesthetic dermatology · 2017Review
- Topical tacrolimus in anterior segment inflammatory disorders.Eye and vision (London, England) · 2017Review
- Clinical features and in vivo confocal microscopy assessment in 12 patients with ocular cicatricial pemphigoid.International journal of ophthalmology · 2016Article
- The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: A review of literature.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2016Review
- Coexistence of mucous membrane pemphigoid and vitiligo.Indian dermatology online journal · 2014Article
- [Not Available].Therapeutics and clinical risk management · 2008Article
- Current Therapeutic Modalities of Immunobullous Lesions.Contemporary clinical dentistryArticle
- Desquamative gingivitis as only presenting sign of mucous membrane pemphigoid.Journal of Indian Society of PeriodontologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucous membrane pemphigoid (MMP) is an autoimmune blistering disorder that is characterized by subepithelial bullae. Various basement membrane zone components have been identified as targets of autoantibodies in MMP. Considerable variability exists in the clinical presentation of MMP. Mucous membranes that may be involved include the oral cavity, conjunctiva, nasopharynx, larynx, esophagus, genitourinary tract, and anus. A multidisciplinary approach is essential in the management of MMP. Early recognition of this disorder and treatment may decrease disease-related complications. The choice of agents for treatment of MMP is based upon the sites of involvement, clinical severity, and disease progression. For more severe disease, or with rapid progression, systemic corticosteroids are the agents of choice for initial treatment, combined with steroid-sparing agents for long-term maintenance. Due to the rarity of this disease, large controlled studies comparing the efficacy of various agents are lacking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.